RxDoctor Payments Data

Kala Mathew

Acute Care · Merrick, NYNPI 1295412146

Payments from drug & device makers

$819in general payments, 2019–2025

Across 32 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$186
  • Merck$96
  • Sanofi$54
  • Johnson & Johnson$52
  • Novartis$49
  • Tersera Therapeutics LLC$49
  • plus $334 from 14 others

What the payments were for

  • Food & beverage$72088%
  • Education$9912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$819 in reported general payments places this provider in the 75th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$8,507
Medicare patients
59
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib26$417,875
RevlimidLenalidomide15$229,799
KisqaliRibociclib Succinate11$149,924
EliquisApixaban21$18,060
XareltoRivaroxaban19$13,057
Letrozole69$1,583
Anastrozole81$1,250
Duloxetine Hcl14$477
Gabapentin13$265
Prochlorperazine Maleate25$245
Ondansetron Hcl17$218
Dexamethasone17$142
Oxycodone Hcl11$101
Acyclovir14$76
Prednisone20$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$49$149,92411 claims
Johnson & JohnsonXarelto$52$13,05719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 980 acute care providers in New York.

Other acute care in Merrick

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →